Rangaprasad Sarangarajan

Chief Scientific Officer & SVP Clinical and Translational Sciences
Rangaprasad (Ranga) Sarangarajan, Ph.D., is the Chief Scientific Officer and SVP Clinical and Translational Sciences at BERG. He oversees all R&D, strategic planning and implementation of workflows for effective translation of discoveries through pharmaceutical and clinical developmental. He is responsible for a robust pipeline of assets in multiple disease indications, from validation of novel disease specific targets to drug discovery/development programs moving into IND enabling FIH proof-of-concept clinical program. Dr. Sarangarajan is an inventor and architect of the BERG Interrogative Biology® technology; currently focused on next generation R & D innovation in the integration of artificial intelligence (AI) based analytics, bioinformatics and RWD/RWE utility for speeding up identification/validation of targets, tractability, drug discovery & pharmaceutical/clinical development. Dr. Sarangarajan has numerous US and international patents (granted and pending), covering areas of the discovery platform, cancer, immunology, inflammation, neurology, metabolic diseases, diabetes, obesity and associated diagnostics.